Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening

E. Boven, H. M. Pinedo, A. H. Van Hattum, P. G. Scheffer, W. H M Peters, C. A M Erkelens, H. M M Schlüper, C. M. Kuiper, J. Van Ark-Otte, G. Giaccone

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


We have established ten transplantable human soft-tissue sarcoma (STS) xenografts grown as subcutaneous tumours in the nude mouse. Nine xenografts originated from patients that needed chemotherapy in the course of their disease. The xenografts were tested for their sensitivity to maximum tolerated doses of five anti-cancer agents. Growth of treated tumours was expressed as a percentage of control tumour growth and a growth inhibition > 75% was measured for doxorubicin in 20% of the STS xenografts, for cyclophosphamide in 30%, for ifosfamide in 20%, for vincristine in 20%, whereas etoposide was not effective in the STS xenografts. In three out of ten STS xenografts MDR1 mRNA was detectable, but this was not related to the resistance against doxorubicin, vincristine or etoposide. Topoisomerase IIα mRNA expression levels did not reflect sensitivity to doxorubicin or etoposide. In all STS tissues, however, these levels were lower than topoisomerase IIα mRNA in a drug-sensitive human ovarian cancer xenograft. Glutathione concentrations and the activities of glutathione S-transferase, glutathione peroxidase and glutathione reductase were not related to resistance against the alkylating agents or doxorubicin. Of interest, in all STS tissues, glutathione S-transferase π was the predominant isoenzyme present. In conclusion, chemosensitivity of the STS xenografts reflects clinical response rates in phase II trials on the same compounds in adult STS patients. Relatively low levels of topoisomerase IIα mRNA may partly account for intrinsic resistance against, for example, doxorubicin. Additional factors must contribute to moderate responsiveness to alkylating agents.

Original languageEnglish (US)
Pages (from-to)1586-1593
Number of pages8
JournalBritish Journal of Cancer
Issue number12
StatePublished - 1998
Externally publishedYes


  • Anti-cancer agents
  • Glutathione
  • Glutathione-dependent enzymes
  • MDR1
  • Soft tissue sarcoma xenografts
  • Topoisomerase IIα

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening'. Together they form a unique fingerprint.

Cite this